Incidence of Severe Liver Injury with Tigecycline
Tigecycline, a glycylcycline antibiotic, carries a risk of hepatotoxicity, including severe liver injury. Clinical trial data show drug-related alanine aminotransferase (ALT) elevations above 10 times the upper limit of normal (ULN) in 0.5% of patients, with severe cases (hepatic failure or injury leading to death) occurring in about 0.2-0.4% across studies.[1][2]
Post-marketing surveillance reports higher rates: the FDA's Adverse Event Reporting System (FAERS) logs 1.3 cases of severe hepatic injury per 1,000 exposed patients, with some progressing to acute liver failure.[3]
How Common in Clinical Trials vs Real-World Use?
In phase 3 trials (n=3,921 patients), 1.7% experienced any liver-related adverse event, but severe injury (ALT >20x ULN or bilirubin >5x ULN with symptoms) affected <0.5%. Complicated intra-abdominal infections saw the highest rates at 0.9%.[1][4]
Real-world data from cohorts like the Tigecycline Evaluation and Surveillance Trial (TEST, n>20,000) report severe hepatotoxicity in 0.1-0.3%, often in patients with comorbidities like diabetes or alcohol use.[2][5]
Risk Factors Driving Higher Incidence
Pre-existing liver disease triples the risk (up to 1.2% incidence). Concomitant use with hepatotoxins (e.g., acetaminophen, statins) or prolonged therapy (>14 days) elevates rates to 2-3%.[3][6] Elderly patients and those with sepsis show 1.5-fold higher odds.[4]
What Counts as 'Severe' Liver Injury?
FDA defines severe as Hy's law cases (ALT >3x ULN + bilirubin >2x ULN without cholestasis) or events causing hospitalization, transplant, or death. Tigecycline triggered 12 such cases in trials (0.3%) and dozens post-approval.[1][3]
Comparison to Other Antibiotics
Tigecycline's severe liver injury rate (0.2-1.3%) exceeds tetracyclines like doxycycline (<0.1%) but matches carbapenems (0.5-1%). It's higher than vancomycin (0.1%) in skin/soft tissue infections.[2][5][7]
| Antibiotic | Severe Liver Injury Rate (%) |
|------------|------------------------------|
| Tigecycline | 0.2-1.3 |
| Doxycycline | <0.1 |
| Meropenem | 0.5-1.0 |
| Vancomycin | 0.1 |
Outcomes and Monitoring Guidelines
Most cases resolve after discontinuation (85-90%), but 5-10% are fatal, often with multi-organ failure.[3][6] Label warns of Class Warning/Precaution for hepatotoxicity; monitor LFTs weekly, especially in at-risk groups.[1]
[1]: Tigecycline Prescribing Information (FDA)
[2]: Clinical Infectious Diseases, 2013: Tigecycline Safety Review
[3]: FDA FAERS Database Analysis, 2022
[4]: JAMA, 2005: Tigecycline Phase 3 Trials
[5]: Int J Antimicrob Agents, 2010: TEST Program
[6]: LiverTox (NIH), Tigecycline Profile
[7]: Antimicrob Agents Chemother, 2018: Comparative Hepatotoxicity